

JC13 Rec'd PCT/PTO 19 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Charanjit Bountra et al.

International App. No.: PCT/GB00/01320 Group Art Unit:

International Filing Date: April 7, 2000 Examiner:

For: MEDICAL USE

**Commissioner for Patents**  
**Washington, D.C. 20231**

**INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[ ] Copies of the references are enclosed

[ ] Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ (37 CFR 1.98(d))

[X] A copy of the International Search Report which issued on International Application No. PCT/GB00/01320 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[ ] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. [ ] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C. [ ] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [ ] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [ ] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

[ ] Please charge any required fees to Deposit Account No.07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

Bonnie L. Deppenbrock  
Bonnie L. Deppenbrock, Attorney of Record  
Registration No. 28,209

Date: 12/18/01

GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1577  
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTORNEY DOCKET NO. PG3733USW	INTL APP. NO. PCT/GB00/02516
			APPLICANT BURBIDGE et al.	
			INTL. FILING DATE June 30, 2000	GROUP

## U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5,384,330	1/24/95	Dieter Hans-Reinhold et al.			

Continue on page \_\_\_\_\_

## FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	BA	99/31232	6/24/99	PCT			
	BB	99/21875	5/6/99	PCT			

Continue on page \_\_\_\_\_

## OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

CA	Rundfeldt, Chris, et al., "The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits", <i>Neuroscience Letters</i> , Vol. 282, No. 1-2, pp. 73-76, March 17, 2000.
CB	Stein, V., et al., "Moderate loss of function of cAMP-modulated KCNQ2 KCNQ3 K+ channels is sufficient to cause epilepsy," <i>Journal of Neurochemistry</i> , July 1999, Vol. 73, Supp. 'S!', pp. S128-S128.
CC	Rundfeldt, Chris, et al., "Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells," <i>Epilepsy Research</i> , 1999, Vol. 35, No. 2, pp. 99-107.
CD	Tinel, Norbert, et al., The KCNQ2 potassium channel: Splice variants, functional and developmental expression. Brian localization and comparison with KCNQ3," <i>FEBS Letters</i> , Vol. 438, No. 3, pp. 171-176, November 6, 1998.
CE	Dost, R., et al., "The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation," <i>Epilepsy Research</i> , 1999, Vol. 38, No. 1, pp. 53-66.
CF	Rundfeldt, C. (reprint), et al., "The anticonvulsant drug retigabine is effective on 4-aminopyridine induced epileptiform activity in vitro," <i>European Journal of Neuroscience</i> , August 1998, Vol. 10, Supp. '10!, pp. 2028-2028.
CG	Tober, C., et al., "D - 23129," <i>Drugs of the Future</i> , 1995, Vol. 20, No. 11, pp. 1112-1115.
CH	Bialer, M. et al., "Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference," <i>Epilepsy Research</i> , 1996, Vol. 25, No. 3, pp. 299-319.
CI	Kapetanovic, I.M., et al., "D-23129: A new anticonvulsant compound," <i>CNS Drug Reviews</i> , 1996, Vol. 2, No. 3, pp. 308-321.

Continue on page \_\_\_\_\_

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.